Last edition
News about "HIV treatment "
US FDA Approves Gilead's Bixlenvo for Once-Daily HIV Treatment
The US Food and Drug Administration (FDA) approves Gilead’s Bixlenvo, a once-daily single-tablet HIV treatment combining bictegravir and lenacapavir for virologically suppressed adults.
HIV Treatment | 01/09/2026 | By News Bureau
Merck Wins FDA Approval for Once-Daily IDVYNSO (Doravirine/Islatravir)
IDVYNSO is approved for adults with virologically suppressed HIV-1 with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.
HIV Treatment | 23/04/2026 | By News Bureau | 216
Bionpharma Wins FDA Approval for Etravirine Tablets in Partnership with STEERLife
The US FDA approval clears the way for Bionpharma to market its generic Etravirine tablets in the US, expanding patient access to a cost-effective HIV treatment option.
HIV Treatment | 14/01/2026 | By News Bureau | 202
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
HIV Treatment | 13/10/2025 | By Dineshwori | 348
MPP-ViiV Agreement Expanded: Aurobindo, Cipla and Viatris to Make Generic HIV Drug Cabotegravir
ViiV Healthcare and the Medicines Patent Pool (MPP) have expanded their voluntary licensing agreement for cabotegravir, enabling manufacturers such as Aurobindo, Cipla, and Viatris to develop, manufacture, and supply generic versions for the HIV treatment in 133 countries.
HIV Treatment | 15/07/2025 | By Dineshwori | 704
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy